6.10

5.43% -0.35

C 4 Therapeutics Inc (CCCC)

Overview News Price History Option Chain Financials Discussions Forecast

C 4 Therapeutics Inc stock is traded at $6.10, with a volume of 1.06M. It is down -5.43% in the last 24 hours and up +13.38% over the past month. C4 Therapeutics Inc is a biopharmaceutical company advancing targeted protein degradation science to develop a new generation of small-molecular medicines to transform how the disease is treated. Its TORPEDO platform enables the discovery of a new class of targeted investigational small-molecule medicines called protein degraders.

Previous Close:

$6.45

Open:

$6.2

24h Volume:

1.06M

Relative Volume:

1.16

Market Cap:

$424.95M

Revenue:

$20.76M

Net Income/Loss:

$-132.49M

P/E Ratio:

-2.1404

EPS:

-2.85

Net Cash Flow:

$-108.55M

1W Performance:

+3.39%

1M Performance:

+13.38%

6M Performance:

-9.50%

1Y Performance:

+291.03%

1-Day Range:

$5.84

$6.3695

1-Week Range:

$5.2219

$6.52

52-Week Range:

$1.06

$11.88

C 4 Therapeutics Inc Stock (CCCC) Company Profile

Name

C 4 Therapeutics Inc

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

(617) 231-0700

Address

490 ARSENAL WAY, WATERTOWN

Employee

145

Twitter

Next Earnings Date

2024-10-30

Latest SEC Filings

CCCC's Discussions on Twitter

C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-24-23	Upgrade	Credit Suisse	Underperform → Neutral
Feb-24-23	Downgrade	JP Morgan	Neutral → Underweight
Nov-04-22	Downgrade	JP Morgan	Overweight → Neutral
Oct-11-22	Initiated	Morgan Stanley	Underweight
Apr-28-22	Initiated	Credit Suisse	Underperform
Apr-11-22	Downgrade	BofA Securities	Buy → Neutral
Mar-10-22	Initiated	JP Morgan	Overweight
Feb-11-22	Resumed	BMO Capital Markets	Outperform
Feb-10-22	Initiated	Wells Fargo	Equal Weight
Nov-23-21	Initiated	BofA Securities	Buy
Oct-14-21	Initiated	SVB Leerink	Mkt Perform
Sep-30-21	Initiated	Stifel	Hold
Jun-04-21	Initiated	H.C. Wainwright	Buy
Mar-31-21	Initiated	BMO Capital Markets	Outperform
Oct-28-20	Initiated	UBS	Buy
Oct-27-20	Initiated	BMO Capital Markets	Outperform
Oct-27-20	Initiated	Jefferies	Buy

View All

C 4 Therapeutics Inc Stock (CCCC) Latest News

09:11 AM

C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin's Lymphoma at the American Society of Hematology (ASH) Annual Meeting - The Manila Times

09:11 AM

09:00 AM

C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin's Lymphoma At the American Society of Hematology Annual Meeting - Marketscreener.com

09:00 AM

07:02 AM

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

07:02 AM

06:30 AM

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

06:30 AM

Nov 04, 2024

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Nov 04, 2024

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Nov 04, 2024

Nov 01, 2024

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Nov 01, 2024

ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Nov 01, 2024

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Nov 01, 2024

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Marketscreener.com

Nov 01, 2024

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Kilgore News Herald

Nov 01, 2024

C4 Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 01, 2024

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Nov 01, 2024

C4 Therapeutics Advances in Protein Degradation Therapy - TipRanks

Nov 01, 2024

Oct 31, 2024